(SWOG) A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta.
More From BioPortfolio on "Immunotherapy combination effective for patients with rare neuroendocrine cancer"